|View printer-friendly version|
|Vitae Pharmaceuticals to Present at Upcoming Meetings|
Vitae will present a poster titled, "The potent, selective RORγt blocker, VTP-43742, suppresses Th17 production in vivo and provides greater benefit than IL-17 blockade in the EAE model of autoimmunity." VTP-43742 is Vitae's novel, potential first-in-class RORγt inhibitor being developed for autoimmune disorders.
The same data will be presented in a poster session.
For more information on IMMUNOLOGY 2015, visit http://immunology2015.org/.
Vitae will present a poster titled "The LXR ligand VTP-38543 represents a new class of therapeutic agents for the treatment of atopic dermatitis." VTP-38543 is Vitae's novel, potential first-in-class LXR ligand being developed for atopic dermatitis.
Arteriosclerosis, Thrombosis, and Vascular Biology Peripheral Vascular Disease 2015 Scientific Sessions
Vitae will present a poster titled "The LXRβ Selective Agonist, VTP-38443, Significantly Decreases Plaque Cholesterol Ester Content and Inflammation in a Murine Model of Accelerated Atherosclerosis." VTP-38443 is Vitae's novel, potential first-in-class LXRβ partial agonist being developed for acute coronary syndrome.
For more information on the Arteriosclerosis, Thrombosis, and Vascular Biology Peripheral Vascular Disease 2015 Scientific Sessions, visit http://my.americanheart.org/professional/Sessions/ATVBPVD/ATVBPVD-Scientific-Sessions_UCM_316902_SubHomePage.jsp.
For additional information, please visit the company's website at www.vitaepharma.com.